Trevena announces presentations on OLINVYK respiratory safety data » 07:1605/1205/12/21
Trevena announced a…
Story temporarily locked.
Trevena announces TRV027 selected by ACTIV initiative for COVID-19 trial » 08:1105/0605/06/21
Trevena announced that…
Trevena announced that TRV027, the company's novel AT1 receptor selective agonist, has been selected for an NIH ACTIV, or Accelerating COVID-19 Therapeutic Interventions and Vaccines, trial in COVID-19 patients. The trial, known as ACTIV-4d RAAS, is a component of the National Heart, Lung, and Blood Institute of the NIH's CONNECTS initiative. The objective of ACTIV-4d RAAS is to evaluate treatments targeting the RAAS and to determine whether modulation of the RAAS is an effective strategy for preventing progression to critical illness, multiorgan failure, or mortality in hospitalized COVID-19 patients.
Trevena expects cash to fund requirements through 4Q22 » 07:1105/0605/06/21
Cash and cash equivalents…
Cash and cash equivalents were $97.7 million as of March 31, 2021, which the Company believes will be sufficient to fund the Company's operating expenses and capital expenditure requirements through the fourth quarter of 2022.
Trevena reports Q1 EPS (6c), consensus (8c) » 07:1005/0605/06/21
Reports Q1 revenue…
Reports Q1 revenue $209,000, consensus $780,000. "In the first quarter, we made significant progress across our business. We continued to expand awareness of OLINVYK with key customers and announced an exciting outcomes study to further enhance the value proposition," said Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. "In parallel, we advanced our pipeline with major new studies for TRV027 in COVID-19 patients, in collaboration with two of the most prominent platform trial networks in the world, and we selected diabetic neuropathic pain as the initial indication for TRV045."
|Over a week ago|
Trevena's TRV027 selected for study in REMAP-CAP trial in COVID-19 patients » 07:0404/2104/21/21
Trevena announced that…
Trevena announced that TRV027, the company's novel AT1 receptor selective agonist, has been selected for inclusion in an international, multi-site, Phase 2-Phase 3 trial in COVID-19 patients. "I am pleased with the addition of TRV027 to REMAP-CAP, a globally recognized research network that is leading the search for cutting-edge COVID-19 therapies," said Carrie Bourdow, President and CEO of Trevena. "TRV027 holds immense potential as a treatment for the severe multi-organ damage and blood clotting caused by COVID-19, and I look forward to supporting the investigation of our novel asset in this innovative and expansive trial." The trial, known as the REMAP-CAP COVID-19 ACE2 RAS Modulation Domain, is designed specifically to evaluate treatments targeting the renin-angiotensin system, or RAS, and determine whether modulation of the RAS is an effective strategy for preventing multiorgan failure and mortality in hospitalized COVID-19 patients.
Trevena announces presentations on OLINVYK health economic models » 07:4204/1504/15/21
Trevena announced two…
Trevena announced two poster presentations at the AMCP 2021 Annual Meeting. The conference was held virtually from April 13th to 14th, 2021. The posters highlight two health economic models developed for OLINVYK injection, which estimate the budget impact of OLINVYK compared to IV morphine when used on-demand in a hospital setting for postoperative pain. A "Base Case" model assumes a broad patient population. A "High Risk" model limits the population to patients who are both elderly and obese, part of the Company's initial core focus for launch. Both models were developed using AE incidence rates from the OLINVYK Phase 3 program and AE cost estimates from the published literature and claims data as referenced in the posters. One of the posters, "Budget Impact Analysis for Oliceridine in the Management of Moderate-to Severe Acute Postoperative Pain," was selected by the conference for a Gold Ribbon. This designation was awarded based on the same criteria used by Journal of Managed Care & Specialty Pharmacy to evaluate manuscripts and was only given to 20% of all submitted abstracts. Poster Details: Base Case Model: "Budget Impact Analysis for Oliceridine in the Management of Moderate-to Severe Acute Postoperative Pain": OLINVYK is associated with a ~$230,000 decrease in total cost of care per 1,000 patients compared to IV morphine. These cost savings are due to reduced AEs for OLINVYK-treated patients, as observed in the Phase 3 pivotal trials, and using a conservative, low-end estimate of AE costs based on government and published literature sources. High Risk Model: "Cost Effectiveness Analysis of Oliceridine Compared with Morphine in The Management of Postoperative Moderate to Severe Acute Pain in a High Risk Population": OLINVYK is associated with savings of ~$364,000 in total cost of care per 1,000 patients, due to reduced AEs compared to IV morphine. The model estimates that the total cost of care associated with IV morphine would exceed $1.25M per 1,000 patients.
|Over a month ago|
Trevena appoints Marvin Johnson to board of directors » 07:1103/1803/18/21
Trevena (TRVN) announced…
Trevena (TRVN) announced that Marvin Johnson, Jr. has been appointed to the Company's Board of Directors, and will stand for election at the 2021 Annual Meeting of Stockholders. Most recently, Mr. Johnson was the Chief Learning Officer for Merck's (MRK) Global Learning and Development department. In conjunction with Mr. Johnson's appointment, the Company announced that Maxine Gowen, Ph.D., and Julie McHugh will be retiring from the Trevena Board of Directors and will not be standing for election at the 2021 Annual Meeting of Stockholders.
Trevena initiated with a Perform at Oppenheimer » 06:3703/1503/15/21
Oppenheimer analyst Leland Gershell initiated coverage of Trevena with a Perform rating and no price target. While he thinks Trevena has "a solid leadership team" and that Olinvyk is an improved opioid compared to morphine in "key respects," Gershell notes the company has the challenging task of launching a new product into a hospital setting still weathering the COVID-19 storm, giving it "limited visibility to performance for several quarters."
Trevena expects cash to fund requirements through 4Q22 » 07:1703/0903/09/21
Cash and cash equivalents…
Cash and cash equivalents were $109.4 million as of December 31, 2020, which the Company believes will be sufficient to fund the Company's operating expenses and capital expenditure requirements through the fourth quarter of 2022.
Trevena reports Q4 EPS (8c), consensus (6c) » 07:1703/0903/09/21
Reports Q revenue…
Reports Q revenue $69,000, consensus $220,000. "2020 was a year of unprecedented achievement for Trevena. We secured U.S. approval of OLINVYK, laid the groundwork for a successful field launch, and partnered with leading institutions to significantly advance our pipeline - all while navigating the challenges that COVID-19 posed to our industry and our communities," said Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. "We enter 2021 with focus and resilience, as we look to deliver a successful first year of launch for OLINVYK and achieve multiple milestone events across our pipeline."